Atomo Diagnostics Limited announced that the Atomo COVID-19 Antigen Test (Nasal, Nasopharyngeal, or Oropharyngeal swab) has been authorised by the New Zealand Ministry of Health under the New Zealand COVID-19 Public Health Response 2020 (Point of Care) Order (the Order). The authorisation covers professional or self-test use and means authorised persons or classes of persons such as NZ District Health Board hospitals, Government agencies, the healthcare workforce, New Zealand-based businesses and pharmacies are all permitted to supply, distribute, and sell the COVID-19 Antigen Test in New Zealand to other authorized persons or classes of persons, and to also use the Test. Atomo announced on 5 October 2021 that it had renegotiated its supply agreement with US manufacturer Access Bio providing the right, but not the obligation, for Atomo to purchase at a fixed price per unit up to 20 million COVID-19 rapid antigen tests (Atomo branded) during Current year 2022 for sale in Australia and New Zealand.